Stocktoria
HALOZYME THERAPEUTICS, INC. HALO
HALOZYME THERAPEUTICS, INC. (HALO) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $1.4B at a 22.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.57 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-05-12 | Morgan Stanley | Overweight (main) |
| 2026-04-29 | HC Wainwright & Co. | Buy (main) |
| 2026-02-19 | Benchmark | Buy (main) |
| 2026-02-19 | Wells Fargo | Equal-Weight (main) |
| 2026-01-08 | TD Cowen | Buy (main) |
| 2025-12-19 | HC Wainwright & Co. | Buy (reit) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.257 |
| Retained earnings / assets | 0.022 |
| EBIT / assets | 0.186 |
| Equity / liabilities | 0.02 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| HALO | HALOZYME THERAPEUTICS, INC. | 5/9 | 3.02 | 28.1 | +37.6% |
| TECH | BIO-TECHNE Corp | 5/9 | 5.89 | 151.4 | +5.2% |
| NVAX | NOVAVAX INC | 4/9 | -7.28 | 3.3 | +64.7% |
| BCRX | BIOCRYST PHARMACEUTICALS INC | 6/9 | -2.63 | 9.6 | +94.1% |
| RGEN | REPLIGEN CORP | 6/9 | 5.48 | 169.6 | +16.4% |
| QGEN | QIAGEN N.V. | 7/9 | 5.06 | 19.1 | +5.7% |
| ADMA | ADMA BIOLOGICS, INC. | 5/9 | 8.8 | 13.8 | +19.6% |
About HALOZYME THERAPEUTICS, INC.
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.
FAQ
Is HALO financially healthy?
HALOZYME THERAPEUTICS, INC.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does HALO pay a dividend?
No, HALOZYME THERAPEUTICS, INC. does not currently pay a dividend.
How profitable is HALO?
In FY2025, HALOZYME THERAPEUTICS, INC. had a net margin of 22.7% and a return on equity of 649.2%.
Is HALO overvalued or undervalued?
HALOZYME THERAPEUTICS, INC. trades at about 39.8× trailing earnings — above its 10-year norm (10-year range 12.6×–52.3×, median 28.0×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for HALO?
The average Wall-Street price target for HALOZYME THERAPEUTICS, INC. is $83.90, about 17.6% below the recent price, from 10 analysts (consensus: buy).
Is HALO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on HALOZYME THERAPEUTICS, INC.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a P/E of about 28.1×. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.